Utility of Mac-2 binding protein glycosylation isomer as an excellent biomarker for the prediction of liver fibrosis, activity, and hepatocellular carcinoma onset: an expert review
Journal of Gastroenterology · 2025
DOI: 10.1007/s00535-024-02179-8 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Gastroenterology, 2025. Verfasst von Yoshihiro Kamada und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Advanced Metabolic Hepatology, Osaka University Graduate School of Medicine, 1-7, Yamadaoka, Suita, Osaka, 565-0871, Japan. Hauptthemen laut MEDLINE: Liver Cirrhosis, Carcinoma, Hepatocellular, Liver Neoplasms, Antigens, Neoplasm. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 105 Literaturangaben.
Abstract (Originalsprache)
Mac-2 binding protein glycosylation isomer (M2BPGi) is a liver fibrosis biomarker that originated in Japan and has been covered by health insurance for 10 years. M2BPGi is useful not only for liver fibrosis stage prediction but also for assessment of the degree of liver inflammation and prediction of hepatocellular carcinoma development. The usefulness of M2BPGi for assessing disease progression in patients with various chronic liver diseases has been demonstrated over the past decade in a large number of patients. Recently, there have been many reports from outside Japan, including reports from South Korea, Taiwan, Hong Kong, and China. These studies demonstrated that M2BPGi is an excellent biomarker that can evaluate the progression of liver fibrosis in chronic liver disease. It is also an excellent indicator of liver activity. Recently, a quantitative M2BPGi (M2BPGi-Qt) assay was developed, and future validation in real-world settings is expected. This will enable diagnosis of the progression of liver fibrosis based on more precise test results and is expected to contribute to the early detection and follow-up of diseases caused by chronic hepatitis, as well as post-treatment monitoring. The significance of the M2BPGi-Qt assay will likely become clearer as real-world data accumulate. If new cutoff values for each chronic liver disease stage and activity level using the M2BPGi-Qt assay are set based on real-world data, it is expected that this will become a useful tool to identify cases of liver fibrosis and monitor the progression of chronic liver disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Advanced Metabolic Hepatology, Osaka University Graduate School of Medicine, 1-7, Yamadaoka, Suita, Osaka, 565-0871, Japan.
- Graduate School of Healthcare Management, International University of Healthcare and Welfare, 4-1-26, Akasaka, Minato-ku, Tokyo, 107-8402, Japan. sumida19701106@yahoo.co.jp.
- Liver Center, Saga University Hospital, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
- Department of Hepatology, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3, Asahimachi, Abeno, Osaka, 545-8585, Japan.
- Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, Suita, Osaka, 565-0871, Japan.
- Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, 3-9, Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.
ORCID-Profile: Yoshihiro Kamada
Zitieren
APA
Kamada, Y., Sumida, Y., Takahashi, H., Fujii, H., Miyoshi, E., Nakajima, A., & Japan Study Group of NAFLD (JSG-NAFLD) (2025). Utility of Mac-2 binding protein glycosylation isomer as an excellent biomarker for the prediction of liver fibrosis, activity, and hepatocellular carcinoma onset: an expert review. Journal of Gastroenterology. https://doi.org/10.1007/s00535-024-02179-8
Vancouver
Kamada Y, Sumida Y, Takahashi H, Fujii H, Miyoshi E, Nakajima A, et al. Utility of Mac-2 binding protein glycosylation isomer as an excellent biomarker for the prediction of liver fibrosis, activity, and hepatocellular carcinoma onset: an expert review. Journal of Gastroenterology. 2025. doi:10.1007/s00535-024-02179-8
BibTeX
@article{Kamada2025,
author = {Kamada, Yoshihiro and Sumida, Yoshio and Takahashi, Hirokazu and Fujii, Hideki and Miyoshi, Eiji and Nakajima, Atsushi and Japan Study Group of NAFLD (JSG-NAFLD), Japan Study Group of NAFLD (JSG-NAFLD)},
title = {Utility of Mac-2 binding protein glycosylation isomer as an excellent biomarker for the prediction of liver fibrosis, activity, and hepatocellular carcinoma onset: an expert review},
journal = {Journal of Gastroenterology},
year = {2025},
doi = {10.1007/s00535-024-02179-8}
}
EUVIMED